Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Sam Afkhami et al.
Summary: The study found that using adenoviral vectors with a multivalent vaccine through intranasal immunization can generate better mucosal immune responses, including local and systemic antibody responses, mucosal tissue-resident memory T cells, and mucosal trained innate immunity, and provide protection against multiple viral variants.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Multidisciplinary Sciences
Huiping Shuai et al.
Summary: The Omicron variant of SARS-CoV-2 shows reduced replication ability in human cells and attenuated pathogenicity in mice compared with the wild-type strain and other variants. It has lower efficiency in using TMPRSS2 and causes the lowest reduction in body weight and mortality rate among the tested strains.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Multidisciplinary Sciences
Rigel Suzuki et al.
Summary: The Omicron variant of SARS-CoV-2 has spread rapidly in several countries and has shown lower fusogenicity and attenuated pathogenicity compared to the Delta variant.
Article
Multidisciplinary Sciences
Peter J. Halfmann et al.
Summary: The recent study by the SAVE/NIAID network shows that the B.1.1.529 Omicron variant causes milder lung disease in rodents, which is consistent with preliminary human clinical data.
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.
Article
Multidisciplinary Sciences
Jinyan Liu et al.
Summary: This study demonstrates that cellular immunity induced by current SARS-CoV-2 vaccines is highly conserved to the Omicron spike protein. Individuals vaccinated with Ad26.COV2.S or BNT162b2 vaccines showed durable spike-specific CD8(+) and CD4(+) T cell responses that were cross-reactive to both the Delta and Omicron variants, including in central and effector memory cellular subpopulations.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Review
Immunology
Paul Moss
Summary: T cell immunity plays a central role in controlling SARS-CoV-2 infection, with early responses correlating with protection. T cell memory provides broad recognition of viral proteins, limiting the impact of viral variants and offering protection against severe disease. Current COVID-19 vaccines elicit robust T cell responses, contributing to the prevention of hospitalization or death. Therefore, the importance of T cell immunity may have been underestimated.
Article
Biochemistry & Molecular Biology
Yu Gao et al.
Summary: This study found that SARS-CoV-2 spike-specific CD4(+) and CD8(+) T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against the Omicron variant. Additionally, T cells induced by BNT162b2 vaccination exhibit higher cross-reactivity to the Omicron variant compared to T cells induced by prior SARS-CoV-2 infection.
Article
Immunology
Flavia Chiuppesi et al.
Summary: Research shows that the COH04S1 vaccine provides effective protection against SARS-CoV-2 in animal models through different vaccination routes and dose regimens. It induces specific immune responses, including cross-neutralizing antibodies, and protects against symptoms and lung damage caused by viral challenge. Additionally, the vaccine also triggers strong immune responses and antiviral reactions in non-human primates.
Article
Biochemistry & Molecular Biology
Matthew Gagne et al.
Summary: This study shows that both mRNA-1273 and mRNA-Omicron generate comparable immunity and protection after booster doses, and are able to neutralize the Omicron variant.
Article
Immunology
Nanda Kishore Routhu et al.
Summary: The study demonstrates that vaccination with MVA/SdFCS-N via the IM route can effectively induce cross-reactive antibody and T cell responses, providing better protection against heterologous SARS-CoV-2 VOCs compared to other vaccination routes.
SCIENCE IMMUNOLOGY
(2022)
Article
Immunology
Jinyi Tang et al.
Summary: SARS-CoV-2 mRNA vaccination induces strong immune responses in the circulation, but its effectiveness in the respiratory tract, especially against variants of concern like Omicron, is still uncertain. This study found lower neutralizing antibody responses in the respiratory tract of vaccinated individuals compared to COVID-19 convalescents, despite robust antibody responses in the blood. Vaccination also induced circulating B and T cell immunity, but these responses were absent in the respiratory tract. Mouse immunization experiments showed that systemic mRNA vaccination alone resulted in weak respiratory mucosal neutralizing antibody responses, but combining it with mucosal adenovirus-S immunization produced strong neutralizing antibody responses against both the ancestral virus and the Omicron variant. Overall, this study suggests that current COVID-19 vaccines are highly effective against severe disease, but provide limited protection against breakthrough infections, particularly by the Omicron sublineage.
SCIENCE IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Jessica A. Plante et al.
Summary: The D614G substitution in the SARS-CoV-2 spike protein enhances viral replication and infectivity in human lung epithelial cells, primary airway tissues, and hamsters. This variant may increase transmission in the upper respiratory tract and doesn't seem to significantly reduce vaccine efficacy. Further research on therapeutic antibodies targeting the circulating G614 virus is recommended.
Article
Multidisciplinary Sciences
Katherine McMahan et al.
Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.
Article
Multidisciplinary Sciences
Zhiqiang Ku et al.
Summary: Antibody cocktails are a promising approach to prevent SARS-CoV-2 escape, with a combination of antibodies CoV2-06 and CoV2-14 identified as effective in preventing viral escape and providing protection in mice, offering new insights for treating COVID-19.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article
Biochemistry & Molecular Biology
Patrick Tang et al.
Summary: mRNA COVID-19 vaccines demonstrate high effectiveness in preventing severe outcomes and death caused by the Delta variant in Qatar, despite lower effectiveness at blocking infection.
Editorial Material
Medicine, General & Internal
John P. Moore et al.
Summary: This article reviews the circulating SARS-CoV-2 genetic variants and the mechanisms of immunity by which they may escape vaccine-induced protection, proposing 6 measures to address these issues, including enhanced variant isolation and testing procedures, and continued adherence to mask-wearing and other established public health measures.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Multidisciplinary Sciences
Annette B. Vogel et al.
Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.
Article
Biochemistry & Molecular Biology
Xuping Xie et al.
Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.
Article
Biochemistry & Molecular Biology
Antonio Muruato et al.
Summary: The study successfully generated a mouse-adapted strain of SARS-CoV-2 using a reverse genetic system, which recapitulates critical elements of human infection, including viral replication in the lung, immune cell infiltration, and significant in vivo disease.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.
Article
Immunology
Katie E. Lineburg et al.
Summary: Efforts are being made to understand the immune response to SARS-CoV-2, with a focus on T cell immunity and cross-recognition with seasonal coronaviruses. Research has shown that the N protein of SARS-CoV-2 induces an immunodominant response and T cells demonstrate cross-reactivity towards certain coronaviruses through specific peptide conformations.
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jianying Liu et al.
Summary: Serum samples from individuals vaccinated with the BNT162b2 vaccine can neutralize various SARS-CoV-2 variants, indicating mass immunization as a central strategy to end the global COVID-19 pandemic.
Review
Virology
Zhihua Bai et al.
Summary: The N protein of SARS-CoV-2 shares high homology with other coronavirus N proteins, indicating its potential significance as a drug target or vaccine candidate. Further research is needed to explore the functional aspects of this protein in controlling the spread of the virus.
Article
Cell Biology
Tanushree Dangi et al.
Summary: Incorporating nucleocapsid as an antigen in SARS-CoV-2 vaccines can improve acute protection in both the lungs and brain, suggesting the inclusion of nucleocapsid in next-generation COVID-19 vaccines is warranted. This finding provides important insights for the development of future vaccines against COVID-19.
Article
Medicine, Research & Experimental
Michelle Meyer et al.
Summary: The study demonstrates that the mRNA-1273 vaccine is effective in hamsters against SARS-CoV-2, inducing robust neutralizing antibodies and reducing disease severity. It also shows the impact of the vaccine on immune cell infiltration, lymphocyte proportion, and antiviral responses conducive to lung health.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Immunology
John S. Tregoning et al.
Summary: The development and rollout of vaccines have brought hope for controlling the COVID-19 pandemic, with vaccines proving highly effective in preventing disease. However, challenges remain in ensuring equitable access to vaccines globally, as well as lessons to be learned for controlling pandemics in the future.
NATURE REVIEWS IMMUNOLOGY
(2021)
Editorial Material
Microbiology
Aiping Wu et al.
CELL HOST & MICROBE
(2020)
Article
Multidisciplinary Sciences
Peng Zhou et al.
Article
Medicine, General & Internal
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Biochemistry & Molecular Biology
Alba Grifoni et al.
Article
Microbiology
Alba Grifoni et al.
CELL HOST & MICROBE
(2020)
Article
Multidisciplinary Sciences
Kizzmekia S. Corbett et al.
Article
Multidisciplinary Sciences
Nina Le Bert et al.
Article
Medicine, General & Internal
Kizzmekia S. Corbett et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Multidisciplinary Sciences
Masaki Imai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Multidisciplinary Sciences
Antonio E. Muruato et al.
NATURE COMMUNICATIONS
(2020)
Article
Immunology
Yanchun Peng et al.
Article
Multidisciplinary Sciences
Flavia Chiuppesi et al.
NATURE COMMUNICATIONS
(2020)
Review
Immunology
Mangalakumari Jeyanathan et al.
NATURE REVIEWS IMMUNOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Francis K. Yoshimoto
Article
Medicine, Research & Experimental
Markus Baiersdoerfer et al.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2019)
Article
Immunology
Joseph Prescott et al.
Article
Biotechnology & Applied Microbiology
Martin A. Maier et al.
Article
Chemistry, Multidisciplinary
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2012)
Article
Virology
Christopher D. Hammerbeck et al.
JOURNAL OF VIROLOGY
(2011)
Review
Cell Biology
H Ponta et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY
(2003)
